PHOENIX--(BUSINESS WIRE)--Zila, Inc. (NASDAQ:ZILAD) today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has issued an indefinite renewal of the marketing authorization for OraTest®, the company’s proprietary oral cancer diagnostic kit. Under the European Union’s (EU) mutual recognition process, the company expects to receive renewal licenses for member states including Finland, Greece, Luxembourg, The Netherlands, Belgium, the U.K. and Portugal, over the next 30 to 60 days. The combined population of these seven countries exceeds 100 million. The company is seeking marketing partners in the seven EU countries.
